Notice
20 May 2025
regulatory compliance, healthcare, fda, chemotherapy, fluorouracil, dihydropyrimidine dehydrogenase
💉FDA Notice on DPD Deficiency and Fluoropyrimidine Drugs
The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of fluorouracil and capecitabine (both fluoropyrimidine chemotherapy drugs). The purposes of the docket establishment are to foster Agency transparency and to solicit input on the currently available information on DPD deficiency and the use of fluorouracil and capecitabine.
Learn More